Business Wire

Mary Kay Inc. Names Dr. Lucy Gildea Chief Brand and Scientific Officer

6.2.2025 19:00:00 CET | Business Wire | Press Release

Share

To empower future growth, iconic beauty and entrepreneurship company Mary Kay Inc. announced today the appointment of Dr. Lucy Gildea as Chief Brand and Scientific Officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250206167665/en/

Mary Kay Inc. Names Dr. Lucy Gildea Chief Brand and Scientific Officer. Gildea and her freshly designed cross-functional team will pioneer a new operating model to power up Mary Kay’s global brand and science aiming for growth and customer loyalty in over 40 markets. (Photo: Mary Kay Inc.)

Gildea and her freshly designed cross-functional team will pioneer a new operating model to power up Mary Kay’s global brand and science aiming for growth and customer loyalty in over 40 markets. In her expanded role, Gildea will shape a powerful brand identity, image, and strategy consistent across all platforms and geographies supported by an impactful product portfolio embracing the ever-evolving needs of consumers. She and her team will activate the brand through engagement strategies harnessing the power of next-gen entrepreneurs and resonant brand storytelling to win the hearts and minds of consumers.

"With her expertise in science and beauty innovation and customer-centric approach, Lucy will lead a strategic chapter of our transformation into the future. The new Global Brand and Science organization will contribute to our mutual business success by enabling our Independent Beauty Consultants to share a transformative brand experience with their customers and thrive as personal beauty advisors, thus reinforcing the unique value proposition of direct selling," said Ryan Rogers, Chief Executive Officer of Mary Kay and grandson of Mary Kay Ash.

Since joining Mary Kay in 2017, Gildea has focused on modernizing and enhancing the company's competitiveness through product innovation and by improving organizational efficiencies. Gildea spent 15 years at Procter & Gamble working primarily in beauty technology and beauty/skin product development. She also held a variety of senior roles including leading development teams for upstream technology and measurement sciences across healthcare, beauty and personal care industries. During her tenure at P&G, Gildea lived in Singapore, advancing her experience with international markets.

"Mary Kay was founded on a dream to enrich women’s lives with a product portfolio rooted in science. I am confident that integrating brand and science is the winning formula to meet global consumer needs and work toward our continued success. I look forward to maximizing synergies across our teams to captivate our Independent Beauty Consultants and invite a new generation of consumers to fall in love with our brand," said Dr. Lucy Gildea, Mary Kay’s Chief Brand and Scientific Officer.

Gildea earned a Ph.D. in Cell and Molecular Biology, Immunology, and Infectious Diseases at the University of Cincinnati College of Medicine and a Postdoctoral Research Fellowship in Immunology in a joint appointment with Cincinnati Children’s Hospital and the University of Cincinnati Department of Immunology. She also holds a Bachelor of Science in Biology from Georgetown College in Georgetown, Kentucky.

Gildea is a passionate STEM advocate for women and girls. She serves as a Board Member at Baylor Scott & White Dallas Foundation and a Board Advisor at Baylor Scott & White Charles A. Sammons Cancer Center.

This leadership appointment by Ryan Rogers honors Mary Kay Ash’s legacy of empowering women. At Mary Kay, women make up 63% of the R&D team, 54% of the executive team, and 63% of the global workforce1.

Did you know:

  • In 2023 and again in 2024, Mary Kay was named the #1 Direct Selling brand of skin care & color cosmetics in the world by Euromonitor International2.
  • Mary Kay holds more than 1,600 patents for products, technologies, and packaging designs in its global portfolio3.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of Independent Beauty Consultants in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on X.

_______________________
1 Source: Women Representation and Leadership at Mary Kay (May 2024).
2 “Source Euromonitor International Limited; Beauty and Personal Care 2024 Edition, value sales at RSP, 2023 data”
3 As of 2023.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250206167665/en/

Contacts

Mary Kay Inc. Corporate Communications
marykay.com/newsroom -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnewsroom.maryk
ay.com%2F&esheet=54201083&newsitemid=20250206167665&lan=en-US&anchor=marykay.com
%2Fnewsroom&index=9&md5=54f905d7ab8fe599beea511210787de9
972.687.5332 or media@mkcorp.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 15:26:00 CET | Press Release

Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at an adjusted PBR of 0.40x, representing a severe 60% discount to its Comprehensive Equity under IFRS17. Align Partners identifies inefficient capital allocation and a lack of independent governance oversight as primary drivers of this persistent undervaluation. The letter notes that DBI’s Return on Required Capital (ROR) of 21.2% significantly lags behind domestic and global peers, reflecting a historical focus on top-line growth over risk-adjusted profitability. This is exacerbated by a passive payout policy and

Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press Release

Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/en/ “You can now potentially study intracellular target engagement for any protein in live cells,” says M

Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press Release

Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V

HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 11:37:00 CET | Press Release

Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming from outside Hong Kong. The HKTDC presents the world’s largest one-s

FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 11:30:00 CET | Press Release

FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integrate FX Spot+ and EBS Market liquidity into their existing FlexFX workflows, accelerating time to market and r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye